瘤原驱动突变对新辅助免疫疗法的结果对可切除非小细胞肺癌患者的影响
Ziyun Shen1,2, Meixin Teng3, Lu Han1
1Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No. 507 Zhengmin Road, Shanghai, 200433, China.
Cancer immunology, immunotherapy : CII
|November 6, 2023
概括
患有KRAS驱动突变的非小细胞肺癌 (NSCLC) 患者对新辅助免疫治疗的反应得到改善. 这表明KRAS突变可能表明免疫性更高,指导未来的治疗策略.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 基因组学就是基因组学.
背景情况:
- 新辅助免疫疗法对可切除的非小细胞肺癌 (NSCLC) 有效.
- 致癌驱动突变可以影响瘤微环境和免疫治疗反应.
研究的目的:
- 研究瘤驱动突变对接受新辅助免疫治疗的NSCLC患者病理反应和长期结果的影响.
- 探索与不同驱动器基因状态相关的转录组特征.
主要方法:
- 对167名用新辅助免疫疗法和手术治疗的NSCLC患者 (IIA-IIIB阶段) 的回顾性分析.
- 基于驱动器瘤基因状态 (KRAS与非KRAS) 的病理反应和结果的比较.
- RNA测序用于分析处理前和后的转录组形状.
主要成果:
- 患有KRAS驱动突变的患者 (n=28) 与非KRAS组 (31.6%) 相比,具有显著更高的重大病理反应率 (60.7%).
- 克拉斯突变是长期无病生存的独立预测因子 (HR=0.10,P=0.032).
- 在免疫治疗后的KRAS突变NSCLC中观察到更高的CD8+T细胞透和免疫相关途径的丰富.
结论:
- 具有KRAS驱动突变的NSCLC患者对新辅助免疫疗法表现出优异的反应,可能是由于免疫性增加.
- 致癌驱动突变状态,特别是KRAS,对于定制NSCLC新辅助治疗策略至关重要.
更多相关视频
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
5.0K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
相关概念视频
01:27Tumor Immunotherapy
533
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
533
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:30Cancer Vaccines
380
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
380